Ambrx, Inc.

Sandra Biroc

Ying Sun

Jason Pinkstaff

Timothy Buss

Zhenwei Miao

Vadim Kraynov

Richard Spence Barnett

Lillian Skidmore

Amha Hewet

Kyle Atkinson

Damien Bresson

Robin Marsden

Shailaja Srinagesh

Agnieszka Szydlik

Delia Ianina Lopez De Valenta

Melissa Neal

Tsotne Javahishvili

Nick Knudsen

Nickolas Knudsen

Kyle C Atkinson

Angieszka Szydlik

Jason K Pinkstaff

Melissa Cook

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Anti-CD70 antibody drug conjugates

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are &#x3b1;CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the &#x3b1;CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives

Growing community of inventors

Alameda, CA, United States of America

Sandra Biroc